SEC Comment Letter for Outlook Therapeutics, (OTLK) — Feb 22, 2017

Outlook Therapeutics, Inc.
Date: Feb. 22, 2017 · CIK: 0001649989 · Accession: 0000000000-17-006021

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-216080

Date

February 22, 2017

Author

/s/ Joseph McCann for

Form

UPLOAD

Company

Outlook Therapeutics, Inc.

Letter

Mail Stop 4 546 February 22, 2017 Pankaj Mohan, Ph.D. President and Chief Executive Officer Oncobiologics, Inc. 7 Clarke Drive Cranbury, New Jersey 08512

Re: Oncobiologics, Inc. Registration Statement on Form S-1 Filed February 15, 2017 File No. 333-216080

Dear Dr. Mohan :

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dorrie Yale at 202 -551-8776 with any questions.

Sincerely,
/s/ Joseph McCann for

Show Raw Text

Mail Stop 4 546
February 22, 2017

Pankaj Mohan, Ph.D.
President and Chief Executive Officer
Oncobiologics, Inc.
7 Clarke Drive
Cranbury, New Jersey 08512

Re: Oncobiologics, Inc.
  Registration Statement on Form S-1
Filed  February 15, 2017
  File No.  333-216080

Dear Dr. Mohan :

This is to advise you that we have not reviewed and will not review your registration
statement.

Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please  contact Dorrie Yale at 202 -551-8776 with any questions.

Sincerely,

 /s/ Joseph McCann for

Suzanne Hayes
Assistant Director
Office of Insurance and Healthcare

cc: Yvan -Claude J. Pierre   —  Cooley LLP

SecProbe.io